Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Oncology advanced practice providers should have comprehensive knowledge and competency in the area of survivorship care. This module explores the considerations and principles of comprehensive survival care of the patient with cancer.
This module explores the considerations and principles of caring for older adults with cancer. Learn assessment tools, care modifications, pharmacologic principles, and treatment considerations specific to older adults with cancer, which will prepare advanced practice providers for the anticipated surge in survivors in this age group.
This comprehensive course will enhance your understanding of hematopoietic stem cell transplant (HSCT) and provide concepts to apply to your care of HSCT patients.
This module explores the considerations and principles of comprehensive survivorship care of patients with cancer. Learn considerations of each treatment modality, psychosocial and spiritual impacts of treatment, best practice, and the essential influence of the advanced practice provider in care of the cancer survivor.
This introductory course provides a foundation for providing care to patients experiencing a cancer diagnosis, treatment complications, or trouble coping. You’ll cover a range of basic topics, from cancer biology, treatments, symptom management, and patient and family care.
Using two agents that target two different receptors more than doubles length of survival for advanced melanoma than a single agent alone, researchers reported at the 2021 American Society of Clinical Oncology annual meeting.
Patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median 5.7 months longer than those in comparison groups, researchers reported in study findings presented at the American Association for Cancer Research 2021 annual meeting.
Completing up to a year of pembrolizumab immunotherapy after surgical resection of stage IIB or IIC melanoma decreases patients’ risk for disease recurrence or death by 35%, according to study findings presented at the European Society for Medical Oncology 2021 annual meeting. The new findings led the U.S. Food and Drug Administration to expand its approval of pembrolizumab to use as adjuvant therapy in both adults and children aged 12 and older with early-stage melanoma.